PBS-Bio uncovers how Unibioscreen drug kills cancer

Discovery could help doctors decide which patients would benefit most

2011-03-10

(Press-News.org) MESA, Ariz. — March 8, 2011 — Predictive Biomarker Sciences (PBS-Bio) has uncovered how the experimental drug UNBS1450, produced by Unibioscreen, kills cancer cells.

Previous studies have shown that over-activity of a gene known as MCL1 can cause cancer cells to grow out of control. PBS-Bio, which is owned in part by the non-profit, Phoenix-based Translational Genomics Research Institute (TGen), co-discovered that UNBS1450 effectively shuts off the gene and induces apoptosis, the cancer cell's normal process of cellular death.

"It's a very nice candidate drug," said Dr. Michael Bittner, a biologist and Principal Investigator of the PBS-Bio technology. Dr. Bittner said UNBS1450 is effective against MCL1 in very low dosages, which means it could potentially be delivered to patients with minimal side effects and low toxicity. MCL1 is prevalent in leukemia, non-small-cell lung cancer, as well as cancers of the prostate and pancreas.

"The presence of MCL1 can be used as a stratification, or predictive, biomarker to help determine which cancer patients are most likely to respond to UNBS1450," said Dr. Edward Smith, co-founder and CEO of PBS-Bio. This would be particularly beneficial, Dr. Smith said, in selecting patients to participate in clinical trials of UNBS1450, and ultimately in helping physicians decide who should be placed on the drug once it is approved for general use.

Steve Weitman, Chief Medical Officer for Unibioscreen, based in Brussels, Belgium, said Unibioscreen has high hopes for the drug UNBS1450.

"Thanks to the critical assistance we received from PBS-Bio, we at Unibioscreen feel confident now that we have a potential biomarker that can be used to facilitate the development of UNBS1450," Weitman said.

In October, Unibioscreen announced it had entered into an agreement with PBS-Bio to get a more in depth understanding of the mechanisms involved in UNBS1450 as a means of optimizing cancer-patient treatment.

To jump-start drug development, PBS-Bio's analysis helps pharmaceutical companies better understand how their drugs work, and identifies biomarkers that can help predict which patients will respond to treatment.

PBS-Bio is providing drug companies with unique real-time looks at how new therapeutics actually work over time within cellular pathways — the so-called mechanisms of action.

UNBS1450 has been in Phase I clinical trials at hospitals in Belgium and the Netherlands. The drug is a hemi-synthetic derivative of a compound identified by Unibioscreen in the root bark of a plant called Calotropis procera. Pre-clinical tests showed that UNBS1450 is very effective against various tumor types with no adverse side effects.

### About Unibioscreen Unibioscreen is a Belgian private specialist oncology company with focus on innovative "first in class" oncology therapeutics. Unibioscreen has successfully discovered, patented and developed a drug candidate currently in clinical trials in cancer patients. Unibioscreen built its competitive edge on exploiting through hemi-synthesis the structure activity relationship (SAR) of natural product chemistry and through development and use of unique technologies and demanding orthotopic models of cancer. More information is available on: www.unibioscreen.com.

Press Contacts:
Steve Weitman
Chief Medical Officer
sjweit@aol.com

About PBS-Bio Predictive Biomarker Sciences Inc. (PBS-Bio) is a privately held corporation based in Mesa, Arizona, and founded in 2006 with funding from private investors, mostly based in Arizona. It is owned in part by the non-profit, Phoenix-based Translational Genomics Research Institute (TGen). The PBS-Bio/TGen collaborative team includes: Dr. Michael Bittner, a biologist, Co-Director of TGen's Computational Biology Division, and Principal Investigator at TGen for the PBS-Bio technology; Dr. Edward Dougherty, an electrical engineer and the other Co-Director of TGen's Computational Biology Division; and Dr. Edward Smith, a medical doctor, an adjunct faculty member of TGen, and co-founder and CEO of PBS-Bio. The three began their collaborations while working under TGen President and Research Director Dr. Jeffrey Trent when Dr. Trent was the Scientific Director of the National Human Genomics Research Institute in Bethesda, Md. Their professional relationships continued after TGen was founded in Phoenix in 2002. For more information, please visit: pbs-bio.com.

Press Contact:
Dr. Edward Smith, M.D.
President and CEO
602-418-9300
edsmith@pbs-bio.com

ELSE PRESS RELEASES FROM THIS DATE:

New mouse models generated for MYH9 genetic disorders

2011-03-10

WASHINGTON, D.C. (March 9, 2011) -- Researchers have created the first mouse models of human MYH9 genetic disorders, which cause several problems -- including enlarged platelets and sometimes fatal kidney disease. The MYH9 gene makes non-muscle myosin II-A protein. This protein plays a critical role in helping cells move to their correct home during embryonic development. Later in life, the protein continues its involvement in cell migration, cell-cell adhesion and also in maintaining cell shape, says Yingfan Zhang, Ph.D., a postdoctoral fellow at the National Heart, ...

Researchers in France and Austria find novel role for calcium channels in pacemaker cell function

2011-03-10

WASHINGTON, D.C. (March 9, 2011) -- Pacemaker cells in the sinoatrial node control heart rate, but what controls the ticking of these pacemaker cells? New research by Angelo Torrente and his colleagues of the M.E. Mangoni group's, reveals, for the first time, a critical functional interaction between Cav1.3 calcium ion (Ca2+) channels and ryanodine-receptor (RyR) mediated Ca2+ signaling. The study also sheds light on a long-standing debate regarding the relative contributions of the 'funny current' generated by ion channels and the RyR dependent spontaneous diastolic ...

New genetic deafness syndrome identified

2011-03-10

WASHINGTON, D.C. (March 9, 2011) -- Ten years ago, scientists seeking to understand how a certain type of feature on a cell called an L-type calcium channel worked created a knockout mouse missing both copies of the CACNA1D gene. The CACNA1D gene makes a protein that lets calcium flow into a cell, transmitting important instructions from other cells. The knockout mice lived a normal life span, but their hearts beat slowly and arrhythmically. They were also completely deaf. Today at the 55th Annual Biophysical Society Meeting in Baltimore, an international team lead ...

Newly identified spider toxin may help uncover novel ways of treating pain and human diseases

2011-03-10

WASHINGTON, D.C. (March 9, 2011) -- Spider venom toxins are useful tools for exploring how ion channels operate in the body. These channels control the flow of ions across cell membranes, and are key components in a wide variety of biological processes and human diseases. A newly identified toxin from the American Funnel Web spider acts on T-type and N-type calcium channels, researchers from the University of California at Riverside have discovered. The toxin offers a new target for studying T-type channels, which play a role in congestive heart failure, hypertension, ...

Gene fusion mechanisms offer new clues to origin of pediatric brain tumors

2011-03-10

March 10, 2011 – A detailed analysis of gene fusions present at high frequency in the most common pediatric brain tumors has been performed for the first time in a study published online today in Genome Research (www.genome.org), shedding new light on how these genomic rearrangements form in the early stages of cancer. Genomic rearrangements, genetic changes that alter the structure of chromosomes, have a positive role in evolution by creating genetic diversity and new genes; however, rearrangements can also predispose to or potentially initiate diseases such as cancer. ...

Web-crawling the brain

2011-03-10

VIDEO: Researchers have created a three-dimensional nanoscale model of a neural circuit using electron microscopy. As a result, the researchers can crawl these vast neural networks much as Google crawls Web... Click here for more information. BOSTON, Mass. (March 9, 2011) — The brain is a black box. A complex circuitry of neurons fires information through channels, much like the inner workings of a computer chip. But while computer processors are regimented with the deft economy ...

UK doctors consistently oppose euthanasia and assisted suicide

2011-03-10

Los Angeles, CA (March 10th, 2011) – A review of research carried out over 20 years suggests that UK doctors appear to consistently oppose euthanasia and physician-assisted suicide (PAS). The findings - which appear in the latest issue of the journal Palliative Medicine, published by SAGE - highlight a gap between doctors' attitudes and those of the UK public. The study, carried out by Dr Ruaidhrí McCormack and colleagues Dr M Clifford and Dr M Conroy at the Department of Palliative Medicine, Milford Care Centre, Limerick, Eire, searched through literature from 1990 to ...

NIST electromechanical circuit sets record beating microscopic 'drum'

2011-03-10

BOULDER, Colo.—Physicists at the National Institute of Standards and Technology (NIST) have demonstrated an electromechanical circuit in which microwaves communicate with a vibrating mechanical component 1,000 times more vigorously than ever achieved before in similar experiments. The microscopic apparatus is a new tool for processing information and potentially could control the motion of a relatively large object at the smallest possible, or quantum, scale. Described in the March 10 issue of Nature,* the NIST experiments created strong interactions between ...

Researchers find smoking may increase risk for lung disease

2011-03-10

Boston, MA – A team of researchers at Brigham and Women’s Hospital (BWH) have found that approximately one out of every twelve adult smokers have abnormal lung densities present on chest computed tomography (CT) images suggestive of interstitial lung disease which is associated with substantial reductions in lung volumes. In addition, despite being positively associated with smoking, these lung densities were inversely not associated with emphysema. This research is published online on March 10th in the New England Journal of Medicine. It is increasingly acknowledged ...

Tiny gems take big step toward battling cancer

2011-03-10

Chemotherapy drug resistance contributes to treatment failure in more than 90 percent of metastatic cancers. Overcoming this hurdle would significantly improve cancer survival rates. Dean Ho, an associate professor of biomedical engineering and mechanical engineering at Northwestern University, believes a tiny carbon particle called a nanodiamond may offer an effective drug delivery solution for hard-to-treat cancers. In studies of liver and breast cancer models in vivo, Ho and a multidisciplinary team of scientists, engineers and clinicians found that a normally lethal ...

PBS-Bio uncovers how Unibioscreen drug kills cancer

ELSE PRESS RELEASES FROM THIS DATE:

LAST 30 PRESS RELEASES: